EAMS | Early Access to Medicines Scheme

Q: EAMS | Early Access to Medicines Scheme

UK Early Access to Medicines Scheme The Early Access to Medicines Scheme (EAMS) is a UK framework enabling patients with serious diseases to access innovative medicines before marketing authorisation. Supervised by the MHRA , it applies to treatments addressing unmet medical needs. The scheme provides early availability of promising therapies while ensuring structured collection of clinical and safety data to support future regulatory and reimbursement decisions.

UK Early Access to Medicines Scheme

The Early Access to Medicines Scheme (EAMS) is a UK framework enabling patients with serious diseases to access innovative medicines before marketing authorisation.

Supervised by the MHRA, it applies to treatments addressing unmet medical needs. The scheme provides early availability of promising therapies while ensuring structured collection of clinical and safety data to support future regulatory and reimbursement decisions.